Renal effects of COX-2-selective inhibitors

American Journal of Nephrology

Volumn 21, Issue 1, 2001, Pages 1-15

  Brater, D Craig ^a   Harris, Cynthia ^a   Redfern, Jan S ^b   Gertz, Barry J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acute renal failure; Celecoxib; COX 2 inhibitors; Glomerular filtration; Hypertension; Nephrotoxicity; Nonsteroidal anti inflammatory drugs; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; KIDNEY PERFUSION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; REVIEW; SODIUM RETENTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; KIDNEY; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0035079023     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046212     Document Type: Review

References (81)

1. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
2. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease
3. Renal syndromes associated with nonsteroidal antiinflammatory drugs
4. Expression of a mitogen-responsive gene encoding prostaglandin syn-thase is regulated by mRNA splicing
5. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
6. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
7. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs
8. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system
9. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
10. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
11. Gastrointestinal toxicity with cele-coxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: A randomized controlled trial
12. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
13. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
14. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
15. Regulation of cyclooxygenase expression in the kidney by dietary salt intake
16. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephropathy
17. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake
18. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
19. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex
20. Angiotensin II stimulates renal cortical cyclooxygenase-2 expression
21. Selective increase of cyclooxygenase-2 expression in a model of renal ablation
22. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension
23. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis
24. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly
25. Paracrine regulation of the renal microcirculation
26. Eicosanoids: Their functions in renal epithelia ion transport
27. 2α reduces urea reabsorption from the rat collecting duct
28. Regulation of renal function by prostaglandin E receptors
29. 1 infusion in man
30. Interaction of renal prostaglandins with the renin-angiotensin and renal adrenergic nervous systems in healthy subjects during dietary changes in sodium intake
31. 2 formation (1)
32. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle: Selective inhibition of the medullary portion
33. 2 across the isolated perfused rabbit collecting tubule
34. Vasopressin in pathophysiological states
35. The role of prostaglandins in NSAID-induced renal dysfunction
36. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiological foundations and clinical implications
37. The renal effects of nonsteroidal antiinflammatory drugs: Summary and recommendations
38. Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency
39. Renal complications associated with use of nonsteroidal anti-inflammatory agents
40. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans
41. Effect of indomethacin on salt and water homeostasis
42. Edema associated with ibuprofen therapy
43. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem
44. Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure
45. Do nonste-roidal anti-inflammatory drugs affect blood pressure? A meta-analysis
46. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure
47. Nonsteroidal anti-inflammatory drugs and antihypertensives
48. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy
49. NSAIDs and increased blood pressure: What is the clinical significance?
50. Antihypertensive efficacy of angiotensin-converting enzyme inhibition and aspirin counteraction
51. Hyperkalemia associated with indomethacin
52. Incidence of hyperkalaemia induced by indomethacin in a hospital population
53. Indomethacin-induced prostaglan-din inhibition with hyperkalemia
54. Role of prostaglandins in renin secretion
55. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men
56. Renal effects of pros-taglandins and clinical adverse effects of non-steroidal anti-inflammatory agents
57. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function
58. The clinical significance of inhibition of renal prostaglandin synthesis
59. Acute interstitial nephritis with glomerulopathy due to non-steroidal anti-inflammatory agents: A review of its clinical spectrum and effects of steroid therapy
60. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
61. Prostaglandin synthase II
62. Cloning and characterization of growth factor inducible cyclooxygenase gene from rat intestinal epithelial cells
63. Tumor-promoter-inducible genes are differentially expressed in the developing mouse
64. Cyclooxygenase-2 in rat nephron development
65. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
66. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
67. Prostaglandin synthesis I gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
68. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
69. Effects of celecoxib and naproxen on renal function in the elderly
70. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
71. Urinary prostaglandins: Identification and origin
72. Measurement of renal and non-renal eicosanoid synthesis
73. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
74. Comparative inhibitory activity of rofecoxib, meloxicam, diclo-fenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers
75. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
76. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet
77. Are selective COX-2 inhibitors nephrotoxic?
78. Are COX-2 selective inhibitors nephrotoxic?
79. Cardiovascular safety profile of rofecoxib in controlled clinical trials